Form 4: Nurix Therapeutics CLO Sells Shares
Statement of Changes in Beneficial Ownership
Chief Legal Officer Christine Ring sold 8,148 shares of Nurix Therapeutics common stock via a 10b5-1 trading plan.
Summary
- Christine Ring, Chief Legal Officer of Nurix Therapeutics, Inc., sold 8,148 shares of common stock.
- The transaction occurred on May 4, 2026.
- The shares were sold at a weighted average price of $16.9624 per share.
- The sale was executed under a pre-established Rule 10b5-1 trading plan.
- Following the transaction, the reporting person retains 18,305 shares of common stock.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as the sale was executed through a pre-arranged 10b5-1 plan, which is standard practice for executive liquidity.
Positives
- The sale was conducted under a pre-planned Rule 10b5-1 trading plan, which is a standard mechanism for executives to sell shares without triggering insider trading concerns.
Negatives
- The transaction represents a reduction in the equity stake held by a key member of the executive leadership team.
Risks
- Insider selling can sometimes be perceived negatively by the market as a signal of management's view on the company's short-term valuation.
Future Outlook
No specific forward-looking guidance regarding company operations was provided in this filing.
Industry Context
StockSavvy.ai notes that routine insider selling via 10b5-1 plans is common in the biotechnology sector and typically reflects personal financial planning rather than a change in corporate strategy or outlook.
Comparison to Industry Standards
- The use of Rule 10b5-1 plans is the industry standard for corporate officers to manage equity holdings while maintaining regulatory compliance.
Stakeholder Impact
- Minimal impact on shareholders as the sale was pre-planned and represents a small portion of the executive's total holdings.
Next Steps
- No future actions or milestones were disclosed in this filing.
Key Dates
| Date | Description |
|---|---|
| 05/04/2026 | Date of the reported stock sale transaction. |
Keywords
Nurix Therapeutics, NRIX, Insider Trading, Form 4, Biotech, Executive Sale
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.